Neurocrine Biosciences (NBIX) Cost of Revenue (2017 - 2026)
Neurocrine Biosciences (NBIX) posted quarterly Cost of Revenue of $23.2 million for Q2 2026, up 125.24% year-over-year from $10.3 million in Q2 2025, and up 68.12% on a QoQ basis from $13.8 million in Q1 2026.
Neurocrine Biosciences (NBIX) Cost of Revenue (2017 - 2026) Analysis & Trends
Neurocrine Biosciences has reported Cost of Revenue for 10 years, with the latest figure at $23.2 million in Q2 2026.
- Cost of Revenue for Q2 2026 came in at $23.2 million, up 125.24% year-over-year; the trailing twelve-month figure through Jun 2026 was $68.6 million (up 86.41% YoY), and the FY2025 annual result was $52.1 million, up 53.24% from the prior year.
- Cost of Revenue improved to $23.2 million in Q2 2026, from $13.8 million in the prior quarter.
- Over five years, Cost of Revenue peaked at $23.2 million in Q2 2026 and troughed at $4.6 million in Q1 2022.
- A 5-year average of $10.3 million and a median of $9.2 million in 2024 frame the typical range for Cost of Revenue.
- The widest annual swing landed in 2023, when Cost of Revenue soared 139.58%; it then retreated 28.57% in 2024.
- A 5-year view of Cost of Revenue shows it stood at $7.7 million in 2022, then increased by 10.39% to $8.5 million in 2023, then rose by 9.41% to $9.3 million in 2024, then jumped by 89.25% to $17.6 million in 2025, then soared by 31.82% to $23.2 million in 2026.
- Per Business Quant data, the three most recent Cost of Revenue figures were $23.2 million in Q2 2026, $13.8 million in Q1 2026, and $17.6 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.80 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.05 Bn | 39.39 Bn | 2.15 Bn | 1.99 Bn |
| 3 | Zoetis | 31.51 Bn | 29.84 Bn | 1.05 Bn | 673.00 Mn |
| 4 | Takeda Pharmaceutical | 28.70 Bn | 22.90 Bn | 5.10 Bn | 2.55 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 99.50 Mn |
| 6 | Viatris | 18.83 Bn | 17.95 Bn | 1.46 Bn | 2.30 Bn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | 23.20 Mn |
| 8 | Elanco Animal Health | 12.06 Bn | 11.53 Bn | 798.00 Mn | 570.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | - |
| 10 | Alkermes | 8.27 Bn | 7.61 Bn | 397.90 Mn | 98.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 23.20 Mn |
| Jun 30, 2026 | 23.20 Mn |
| Mar 31, 2026 | 13.80 Mn |
| Mar 31, 2026 | 13.80 Mn |
| Dec 31, 2025 | 17.60 Mn |
| Dec 31, 2025 | 17.60 Mn |
| Sep 30, 2025 | 14.00 Mn |
| Sep 30, 2025 | 14.00 Mn |
| Jun 30, 2025 | 11.30 Mn |
| Jun 30, 2025 | 11.30 Mn |
| Mar 31, 2025 | 9.20 Mn |
| Mar 31, 2025 | 9.20 Mn |
| Dec 31, 2024 | 9.30 Mn |
| Dec 31, 2024 | 9.30 Mn |
| Sep 30, 2024 | 8.00 Mn |
| Sep 30, 2024 | 8.00 Mn |
| Jun 30, 2024 | 9.20 Mn |
| Jun 30, 2024 | 9.20 Mn |
| Mar 31, 2024 | 7.50 Mn |
| Mar 31, 2024 | 7.50 Mn |